Literature DB >> 3490197

Evidence for BoLA-linked resistance and susceptibility to subclinical progression of bovine leukaemia virus infection.

H A Lewin, D Bernoco.   

Abstract

The role of the bovine major histocompatibility complex in bovine leukaemia virus (BLV) infection and disease progression was investigated in a herd of Shorthorn cattle (n = 117). The frequency of cows that were seropositive to BLV-glycoprotein antigen was 51%. Twenty-three per cent of the seropositive cows were lymphocytotic. At the herd level, relative resistance to BLV-dependent B-cell proliferation and lymphocytosis among seropositive cows was associated with bovine lymphocyte antigen (BoLA)-DA7, whereas susceptibility was associated with BoLA-DA12.3. These associations were also confirmed at the family level, where BoLA phenotypes were used as haplotypic markers. Among the offspring of one BoLA-heterozygous sire (n = 33), resistance segregated with the DA7 haplotype and susceptibility with the DA12.3 haplotype. In this sire group, maternal transmission of the BoLA-w8 allele was associated with increased susceptibility to B-cell proliferation and lymphocytosis in w8/DA12.3 heterozygotes. These data provide the first evidence that subclinical progression of BLV infection is under the control of the BoLA complex, and suggest that the BoLA system can be used to select for resistance to B-cell proliferation and the development of lymphocytosis in BLV-infected herds.

Entities:  

Mesh:

Year:  1986        PMID: 3490197     DOI: 10.1111/j.1365-2052.1986.tb03191.x

Source DB:  PubMed          Journal:  Anim Genet        ISSN: 0268-9146            Impact factor:   3.169


  20 in total

1.  Development of persistent lymphocytosis in cattle is closely associated with DRB2.

Authors:  M J van Eijk; J A Stewart-Haynes; J E Beever; R L Fernando; H A Lewin
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

Review 2.  Disease resistance in farm animals.

Authors:  M Müller; G Brem
Journal:  Experientia       Date:  1991-09-15

3.  Production and related variables in bovine leukaemia virus-infected cows.

Authors:  R M Jacobs; J L Heeney; M A Godkin; K E Leslie; J A Taylor; C Davies; V E Valli
Journal:  Vet Res Commun       Date:  1991       Impact factor: 2.459

4.  Profile of Harris A. Lewin.

Authors:  Beth Azar
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-12       Impact factor: 11.205

5.  Milk and fat production in dairy cattle influenced by advanced subclinical bovine leukemia virus infection.

Authors:  M C Wu; R D Shanks; H A Lewin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

6.  Effects of bovine leukemia virus infection on production and reproduction in dairy cattle.

Authors:  F L Pollari; V L Wangsuphachart; R F DiGiacomo; J F Evermann
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

7.  Evidence for linkage between the caprine leucocyte antigen (CLA) system and susceptibility to CAE virus-induced arthritis in goats.

Authors:  G Ruff; S Lazary
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

8.  Association between BoLA and subclinical bovine leukemia virus infection in a herd of Holstein-Friesian cows.

Authors:  H A Lewin; M C Wu; J A Stewart; T J Nolan
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

Review 9.  Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV.

Authors:  Sabrina M Rodríguez; Arnaud Florins; Nicolas Gillet; Alix de Brogniez; María Teresa Sánchez-Alcaraz; Mathieu Boxus; Fanny Boulanger; Gerónimo Gutiérrez; Karina Trono; Irene Alvarez; Lucas Vagnoni; Luc Willems
Journal:  Viruses       Date:  2011-07-19       Impact factor: 5.048

10.  Detection of bovine leukemia virus in brains of cattle with a neurological syndrome: pathological and molecular studies.

Authors:  Rubens Henrique Ramos D'Angelino; Edviges Maristela Pituco; Eliana Monteforte Cassaro Villalobos; Ricardo Harakava; Fábio Gregori; Claudia Del Fava
Journal:  Biomed Res Int       Date:  2013-04-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.